In 2001, the first oral targeted therapy authorized for CML was imatinib, an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI) therapy that selectively blocks the activity of ABL kinases [2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.